STOCK TITAN

Cerenome, Inc. (CNSY) rebrands from Plus Therapeutics with new ticker

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Cerenome, Inc., formerly Plus Therapeutics, Inc., implemented a corporate name change effective August 3, 2026. A Certificate of Amendment to its Amended and Restated Certificate of Incorporation was filed in Delaware on July 30, 2026 to effect this change.

In connection with the name change, the company’s common stock, par value $0.001 per share, began trading on the Nasdaq Capital Market under the new ticker symbol “CNSY” at the start of trading on August 3, 2026. The company states that there is no change to its CUSIP as a result of the name or trading symbol change, and it has updated its bylaws to reflect the new corporate name.

Positive

  • None.

Negative

  • None.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Effective date of name change August 3, 2026 Date corporate name changed from Plus Therapeutics, Inc. to Cerenome, Inc.
Amendment filing date July 30, 2026 Date Certificate of Amendment was filed with Delaware Secretary of State
Par value of common stock $0.001 per share Par value of Cerenome, Inc. common stock listed on the Nasdaq Capital Market
Certificate of Amendment regulatory
"filed a Certificate of Amendment to its Amended and Restated Certificate"
A certificate of amendment is an official filing that updates a company’s founding documents—its legal “rulebook” that sets share structure, voting rules, name and basic purpose. Think of it like changing the blueprint of a building: small changes are paperwork, big ones can alter who owns how much and who controls decisions. Investors watch these filings because they can affect share counts, voting power, dilution and company value.
Amended and Restated Certificate of Incorporation regulatory
"Certificate of Amendment to its Amended and Restated Certificate of Incorporation"
A company’s amended and restated certificate of incorporation is an updated version of its foundational legal charter that replaces the older document and folds in all changes into one clear copy; it spells out corporate structure, classes of stock, shareholder rights and key governance rules. Investors care because it can change who controls the company, how votes are counted, what claims shareholders have on assets or dividends, and can introduce or remove protections against takeovers—like updating a house title after a major renovation to show who owns what and under what rules.
CUSIP financial
"There will be no change to the Company’s CUSIP in connection with the Name Change"
A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.
Inline XBRL technical
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What corporate change did PSTV (now Cerenome, Inc.) disclose?

The company changed its corporate name from Plus Therapeutics, Inc. to Cerenome, Inc., effective August 3, 2026, by filing a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Delaware Secretary of State.

When did Cerenome, Inc. (PSTV) file the amendment for its name change?

Cerenome, Inc. filed the Certificate of Amendment on July 30, 2026. The amendment changed the corporate name from Plus Therapeutics, Inc. to Cerenome, Inc., with the name change becoming effective on August 3, 2026.

What is the new Nasdaq trading symbol for Cerenome, Inc. (PSTV)?

The company’s common stock now trades on the Nasdaq Capital Market under the symbol “CNSY”. Shares of common stock began trading under this new ticker at the commencement of trading on August 3, 2026.

Did Cerenome, Inc. change its CUSIP with the new name and ticker?

No, the company states there will be no change to its CUSIP in connection with either the corporate name change to Cerenome, Inc. or the Nasdaq trading symbol change to “CNSY”.

What is the par value of Cerenome, Inc.’s common stock after the name change?

The company’s common stock continues to have a par value of $0.001 per share. The name and ticker symbol changes do not alter the par value or basic terms of the existing common stock.

Which corporate governance documents did Cerenome, Inc. update?

Cerenome, Inc. submitted a Certificate of Amendment to its Amended and Restated Certificate of Incorporation and also provided updated bylaws reflecting the new corporate name, both of which became effective on August 3, 2026.
--12-31false000109598100010959812026-08-032026-08-03

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 3, 2026

CERENOME, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-34375

33-0827593

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

6420 Levit Green Boulevard

Suite 310

Houston, Texas

77021

(Address of Principal Executive Offices)

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (737) 255-7194

 

PLUS THERAPEUTICS, INC.

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.001

 

CNSY

 

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


 

 

Item 5.03. Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On July 30, 2026, Cerenome, Inc. (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Amendment”), with the Secretary of State of the State of Delaware to effect a change of the Company’s corporate name from “Plus Therapeutics, Inc.” to “Cerenome, Inc.” (the “Name Change”), effective August 3, 2026. The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 3.1 to this Current Report on Form 8-K (this “Form 8-K”) and is incorporated herein by reference.

 

In connection with the Name Change, the Company changed its trading symbol for its common stock, par value $0.001 per share (the “Common Stock”) on the Nasdaq Capital Market to “CNSY.” The shares of Common Stock began trading under the new symbol at the commencement of trading on August 3, 2026. There will be no change to the Company’s CUSIP in connection with the Name Change or the trading symbol change.

 

The Company’s bylaws reflecting the Name Change is filed as Exhibit 3.2 to this Form 8-K.

Item 9.01 Financial Statements and Exhibits.

 

Exhibit

Number

Description

3.1

 

Certificate of Amendment to Amended and Restated Certificate of Incorporation, as amended, effective August 3, 2026.

3.2

 

Bylaws of Cerenome, Inc., effective August 3, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

CERENOME, INC.

Date: August 4, 2026

By:

/s/ Andrew Sims

Name: Andrew Sims

Title: Chief Financial Officer

 

2


Filing Exhibits & Attachments

3 documents